Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first patient dosing in a Phase Ib/II clinical study for its antibody-drug conjugate (ADC) 9MW2821, which targets Nectin-4. The study is designed to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of 9MW2821 in combination with a PD-1 inhibitor for the treatment of locally advanced or metastatic urothelial carcinoma (UC).
9MW2821: A Promising ADC for Urothelial Carcinoma
9MW2821 is an innovative antibody-drug conjugate that is being investigated for its potential in treating a range of advanced solid tumors, including urothelial carcinoma (UC), cervical cancer, prostate cancer, HER2-negative breast cancer, and non-small cell lung cancer. The molecule’s unique mechanism of action targets Nectin-4, a protein overexpressed in various cancers, making it a promising candidate for targeted cancer therapy.
Clinical Study Design and Significance
The Phase Ib/II study will provide valuable insights into the combination therapy’s safety profile, tolerability, and preliminary efficacy in patients with UC. By combining 9MW2821 with a PD-1 inhibitor, the study aims to assess whether the synergistic effect of this combination can improve treatment outcomes for patients with locally advanced or metastatic UC. The pharmacokinetic data generated from this study will also be crucial for understanding the drug’s behavior in the body and optimizing its dosage regimen.-Fineline Info & Tech
